Statutory notification of infectious diseases provides a means to alert public health officials to the occurrence of suspected or confirmed case of a given disease to direct public health action to prevent infection in others. These regulations, standards and guidance can be viewed at the following links:<\/p>
http://www.legislation.gov.uk/uksi/2010/659/contents/made<\/a><\/p> https://www.gov.uk/guidance/notifiable-diseases-and-causative-organisms-how-to-report<\/a><\/p> The majority of infant Group B Streptococcus cases occur sporadically rather than through spread between individuals. As such, there are no specific public health actions recommended at present following the identification of a single case. If new evidence emerges to suggest actions should be initiated, the addition of Group B Streptococcus to the schedule of notifiable diseases will be reviewed.<\/p> <\/strong><\/p> <\/strong><\/p>"}
, "answeringMember" : {"_about" : "http://data.parliament.uk/members/4455", "label" : {"_value" : "Biography information for Seema Kennedy"}
}
, "answeringMemberConstituency" : {"_value" : "South Ribble"}
, "answeringMemberPrinted" : {"_value" : "Seema Kennedy"}
, "dateOfAnswer" : {"_value" : "2019-06-27", "_datatype" : "dateTime"}
, "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
, "questionFirstAnswered" : [{"_value" : "2019-06-27T15:40:30.23Z", "_datatype" : "dateTime"}
]}
, "answeringDeptId" : {"_value" : "17"}
, "answeringDeptShortName" : {"_value" : "Health and Social Care"}
, "answeringDeptSortName" : {"_value" : "Health and Social Care"}
, "date" : {"_value" : "2019-06-19", "_datatype" : "dateTime"}
, "hansardHeading" : {"_value" : "Streptococcus"}
, "houseId" : {"_value" : "1"}
, "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
}
], "questionText" : "To ask the Secretary of State for Health and Social Care, pursuant to the Answer of 19 March 2019 to Question 230615, and with reference to evidence demonstrating a reduction in rates of Group B Streptococcus infection in Northern Ireland since mandatory reporting of confirmed cases in babies was introduced there in March 2013, if he will make an assessment of the potential merits of making Group B Streptococcus a notifiable disease.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
, "tablingMember" : {"_about" : "http://data.parliament.uk/members/4131", "label" : {"_value" : "Biography information for Jim Shannon"}
}
, "tablingMemberConstituency" : {"_value" : "Strangford"}
, "tablingMemberPrinted" : [{"_value" : "Jim Shannon"}
], "uin" : "266696"}
, {"_about" : "http://data.parliament.uk/resources/1133135", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"}
], "answer" : {"_about" : "http://data.parliament.uk/resources/1133135/answer", "answerText" : {"_value" : " In England, local authorities have the lead responsibility for improving the oral health of children and adults in their local area. Further information is available at the following link:<\/p> http://www.legislation.gov.uk/uksi/2012/3094/pdfs/uksi_20123094_en.pdf<\/a><\/p> Improving the oral health of children is a priority for Public Health England (PHE). PHE has established a Child Oral Health Improvement Programme Board, which brings together key stakeholder organisations. The board has a shared ambition that every child grows up free of tooth decay as part of getting the best start in life.<\/p> PHE established an Adult Oral Health Oversight Group, which brings together a wide range of stakeholders that have policies or areas of interest to improve the oral health of adults.<\/p> The Department is testing a new prevention focussed National Health Service dental contract which includes preventive advice and treatment based on \u2018Delivering better oral health\u2019, an evidence-based toolkit for prevention. More information about the dental contract reform programme can be found at the following link:<\/p> https://www.gov.uk/government/collections/dental-contract-reform-prototypes<\/a><\/p>"}
, "answeringMember" : {"_about" : "http://data.parliament.uk/members/4455", "label" : {"_value" : "Biography information for Seema Kennedy"}
}
, "answeringMemberConstituency" : {"_value" : "South Ribble"}
, "answeringMemberPrinted" : {"_value" : "Seema Kennedy"}
, "dateOfAnswer" : {"_value" : "2019-06-27", "_datatype" : "dateTime"}
, "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
, "questionFirstAnswered" : [{"_value" : "2019-06-27T12:44:49.54Z", "_datatype" : "dateTime"}
]}
, "answeringDeptId" : {"_value" : "17"}
, "answeringDeptShortName" : {"_value" : "Health and Social Care"}
, "answeringDeptSortName" : {"_value" : "Health and Social Care"}
, "date" : {"_value" : "2019-06-19", "_datatype" : "dateTime"}
, "hansardHeading" : {"_value" : "Dental Health"}
, "houseId" : {"_value" : "1"}
, "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
}
], "questionText" : "To ask the Secretary of State for Health and Social Care, what steps his Department is taking to prevent tooth decay in (a) children and (b) adults.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
, "tablingMember" : {"_about" : "http://data.parliament.uk/members/1597", "label" : {"_value" : "Biography information for David Simpson"}
}
, "tablingMemberConstituency" : {"_value" : "Upper Bann"}
, "tablingMemberPrinted" : [{"_value" : "David Simpson"}
], "uin" : "266699"}
, {"_about" : "http://data.parliament.uk/resources/1133139", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"}
], "answer" : {"_about" : "http://data.parliament.uk/resources/1133139/answer", "answerText" : {"_value" : " In order for a human medicinal product to be granted a marketing authorisation, legislation requires robust data to be generated to demonstrate satisfactory quality, safety and efficacy of the proposed medicinal product and show that the benefit to risk balance is positive in the intended patient group.<\/p> Studies to evaluate the toxicity profile of a medicine using in vitro or animal models are generally performed, prior to initial safety studies (Phase I) in human volunteers. Further clinical trials (Phase II and III) are then typically performed to establish safety and efficacy in patients, prior to the submission of a marketing authorisation application.<\/p> The Medicines and Healthcare products Regulatory Agency (MHRA) is responsible for the regulation of medicines in the United Kingdom. At this time, the MHRA is not aware of any clinical trials having been planned or conducted on a product that is for oral administration to enable imaging or identification of breast cancer. Therefore, at present, it cannot provide a timeline for the licensing of such a medicine.<\/p>"}
, "answeringMember" : {"_about" : "http://data.parliament.uk/members/4455", "label" : {"_value" : "Biography information for Seema Kennedy"}
}
, "answeringMemberConstituency" : {"_value" : "South Ribble"}
, "answeringMemberPrinted" : {"_value" : "Seema Kennedy"}
, "dateOfAnswer" : {"_value" : "2019-06-27", "_datatype" : "dateTime"}
, "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
, "questionFirstAnswered" : [{"_value" : "2019-06-27T13:02:56.187Z", "_datatype" : "dateTime"}
]}
, "answeringDeptId" : {"_value" : "17"}
, "answeringDeptShortName" : {"_value" : "Health and Social Care"}
, "answeringDeptSortName" : {"_value" : "Health and Social Care"}
, "date" : {"_value" : "2019-06-19", "_datatype" : "dateTime"}
, "hansardHeading" : {"_value" : "Breast Cancer: Diagnosis"}
, "houseId" : {"_value" : "1"}
, "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
}
], "questionText" : "To ask the Secretary of State for Health and Social Care, what information he holds on the timescale for licensing the pill to identify breast cancer.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
, "tablingMember" : {"_about" : "http://data.parliament.uk/members/4131", "label" : {"_value" : "Biography information for Jim Shannon"}
}
, "tablingMemberConstituency" : {"_value" : "Strangford"}
, "tablingMemberPrinted" : [{"_value" : "Jim Shannon"}
], "uin" : "266702"}
, {"_about" : "http://data.parliament.uk/resources/1133146", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"}
], "answer" : {"_about" : "http://data.parliament.uk/resources/1133146/answer", "answerText" : {"_value" : " The commissioning and configuration of rheumatoid arthritis services in England is a local matter. The local National Health Service is best placed to make decisions that ensure services meet the needs of resident populations in the most appropriate way. Service should be planned and delivered in line with the best available evidence, such as National Institute for Health and Care Excellence guidance.<\/p> Regarding assessment, in May 2018, a new three-year Rheumatoid and Early Inflammatory Arthritis Audit was commissioned by the Healthcare Quality Improvement Partnership. More information can be found at the following link:<\/p> www.rheumatology.org.uk/Knowledge/Excellence/Audits<\/a><\/p> The findings of the Audit are due to be published in October 2019. However, previous Audit reports can be found at the following link:<\/p> www.hqip.org.uk/national-programmes/a-z-of-nca/arthritis-rheumatoid-and-early-inflammatory<\/a><\/p>"}
, "answeringMember" : {"_about" : "http://data.parliament.uk/members/4455", "label" : {"_value" : "Biography information for Seema Kennedy"}
}
, "answeringMemberConstituency" : {"_value" : "South Ribble"}
, "answeringMemberPrinted" : {"_value" : "Seema Kennedy"}
, "dateOfAnswer" : {"_value" : "2019-06-24", "_datatype" : "dateTime"}
, "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
, "questionFirstAnswered" : [{"_value" : "2019-06-24T16:55:48.793Z", "_datatype" : "dateTime"}
]}
, "answeringDeptId" : {"_value" : "17"}
, "answeringDeptShortName" : {"_value" : "Health and Social Care"}
, "answeringDeptSortName" : {"_value" : "Health and Social Care"}
, "date" : {"_value" : "2019-06-19", "_datatype" : "dateTime"}
, "hansardHeading" : {"_value" : "Arthritis: Health Services"}
, "houseId" : {"_value" : "1"}
, "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
}
], "questionText" : "To ask the Secretary of State for Health and Social Care, what assessment he has made of the adequacy of the provision of NHS services for people with rheumatoid arthritis.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
, "tablingMember" : {"_about" : "http://data.parliament.uk/members/413", "label" : {"_value" : "Biography information for Hilary Benn"}
}
, "tablingMemberConstituency" : {"_value" : "Leeds Central"}
, "tablingMemberPrinted" : [{"_value" : "Hilary Benn"}
], "uin" : "266693"}
, {"_about" : "http://data.parliament.uk/resources/1133150", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"}
], "answer" : {"_about" : "http://data.parliament.uk/resources/1133150/answer", "answerText" : {"_value" : " No such discussions have taken place.<\/p>"}
, "answeringMember" : {"_about" : "http://data.parliament.uk/members/4455", "label" : {"_value" : "Biography information for Seema Kennedy"}
}
, "answeringMemberConstituency" : {"_value" : "South Ribble"}
, "answeringMemberPrinted" : {"_value" : "Seema Kennedy"}
, "dateOfAnswer" : {"_value" : "2019-06-27", "_datatype" : "dateTime"}
, "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
, "questionFirstAnswered" : [{"_value" : "2019-06-27T12:46:58.39Z", "_datatype" : "dateTime"}
]}
, "answeringDeptId" : {"_value" : "17"}
, "answeringDeptShortName" : {"_value" : "Health and Social Care"}
, "answeringDeptSortName" : {"_value" : "Health and Social Care"}
, "date" : {"_value" : "2019-06-19", "_datatype" : "dateTime"}
, "hansardHeading" : {"_value" : "Cancer: Vitamin D"}
, "houseId" : {"_value" : "1"}
, "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
}
], "questionText" : "To ask the Secretary of State for Health and Social Care, whether he has discussed the potential link between consumption of vitamin D supplements and reduced risk of developing cancer with (a) the Royal College of Nursing and (b) the General Medical Council.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
, "tablingMember" : {"_about" : "http://data.parliament.uk/members/4131", "label" : {"_value" : "Biography information for Jim Shannon"}
}
, "tablingMemberConstituency" : {"_value" : "Strangford"}
, "tablingMemberPrinted" : [{"_value" : "Jim Shannon"}
], "uin" : "266710"}
, {"_about" : "http://data.parliament.uk/resources/1133151", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"}
], "answer" : {"_about" : "http://data.parliament.uk/resources/1133151/answer", "answerText" : {"_value" : " The National Institute for Health and Care Excellence (NICE) is the independent body that provides guidance on the prevention and treatment of ill health and the promotion of good health and social care. Through its technology appraisal programme, NICE makes recommendations for the National Health Service on whether selected drugs and other treatments represent an effective use of NHS resources. NHS commissioners are legally required to fund drugs and treatments recommended through NICE\u2019s technology appraisal programme.<\/p> <\/p> NICE is currently developing technology appraisal guidance on two drugs for the prevention of migraines; erenumab and fremanuzumab. The expected date of NICE\u2019s final guidance is currently to be confirmed. In the absence of positive guidance from NICE, it is for commissioners to make decisions on whether to fund this treatment based on an assessment of the available evidence.<\/p> <\/p> <\/p> <\/strong><\/p> <\/strong><\/p>"}
, "answeringMember" : {"_about" : "http://data.parliament.uk/members/4455", "label" : {"_value" : "Biography information for Seema Kennedy"}
}
, "answeringMemberConstituency" : {"_value" : "South Ribble"}
, "answeringMemberPrinted" : {"_value" : "Seema Kennedy"}
, "dateOfAnswer" : {"_value" : "2019-06-27", "_datatype" : "dateTime"}
, "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
, "questionFirstAnswered" : [{"_value" : "2019-06-27T15:48:35.54Z", "_datatype" : "dateTime"}
]}
, "answeringDeptId" : {"_value" : "17"}
, "answeringDeptShortName" : {"_value" : "Health and Social Care"}
, "answeringDeptSortName" : {"_value" : "Health and Social Care"}
, "date" : {"_value" : "2019-06-19", "_datatype" : "dateTime"}
, "hansardHeading" : {"_value" : "Migraines: Drugs"}
, "houseId" : {"_value" : "1"}
, "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
}
], "questionText" : "To ask the Secretary of State for Health and Social Care, what plans the NHS has to introduce new drugs to tackle migraines in the next six months.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
, "tablingMember" : {"_about" : "http://data.parliament.uk/members/4131", "label" : {"_value" : "Biography information for Jim Shannon"}
}
, "tablingMemberConstituency" : {"_value" : "Strangford"}
, "tablingMemberPrinted" : [{"_value" : "Jim Shannon"}
], "uin" : "266711"}
, {"_about" : "http://data.parliament.uk/resources/1133166", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"}
], "answer" : {"_about" : "http://data.parliament.uk/resources/1133166/answer", "answerText" : {"_value" : " In line with routine clinical practice patients wishing to seek a second opinion will be supported to do so. In the first instance clinicians should refer patients for a second opinion using their established protocols. If it is not possible to obtain a second or further opinion using established protocols then National Health Service trusts are instructed to contact their NHS England Regional Medical Director who will be able to offer further advice around a referral route. The NHS England Regional Medical Directors will support NHS trusts in identifying a suitable NHS specialist for a second opinion. Processes may differ in Scotland, Wales and Northern Ireland.<\/p>"}
, "answeringMember" : {"_about" : "http://data.parliament.uk/members/4455", "label" : {"_value" : "Biography information for Seema Kennedy"}
}
, "answeringMemberConstituency" : {"_value" : "South Ribble"}
, "answeringMemberPrinted" : {"_value" : "Seema Kennedy"}
, "dateOfAnswer" : {"_value" : "2019-06-27", "_datatype" : "dateTime"}
, "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
, "questionFirstAnswered" : [{"_value" : "2019-06-27T12:42:09.417Z", "_datatype" : "dateTime"}
]}
, "answeringDeptId" : {"_value" : "17"}
, "answeringDeptShortName" : {"_value" : "Health and Social Care"}
, "answeringDeptSortName" : {"_value" : "Health and Social Care"}
, "date" : {"_value" : "2019-06-19", "_datatype" : "dateTime"}
, "hansardHeading" : {"_value" : "Cannabis: Medical Treatments"}
, "houseId" : {"_value" : "1"}
, "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
}
], "questionText" : "To ask the Secretary of State for Health and Social Care, whether patients whose prescription for a cannabis-based medical product is blocked by an NHS trust can appeal that decision.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
, "tablingMember" : {"_about" : "http://data.parliament.uk/members/4623", "label" : {"_value" : "Biography information for Tonia Antoniazzi"}
}
, "tablingMemberConstituency" : {"_value" : "Gower"}
, "tablingMemberPrinted" : [{"_value" : "Tonia Antoniazzi"}
], "uin" : "266861"}
, {"_about" : "http://data.parliament.uk/resources/1133167", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"}
], "answer" : {"_about" : "http://data.parliament.uk/resources/1133167/answer", "answerText" : {"_value" : " The Department is in regular contact with the National Institute for Health and Care Excellence (NICE) and NHS England colleagues about a range of issues and has not met with drug manufacturers on funding of licensed cannabis-based products.<\/p> Sativex is currently the only licensed cannabis-based product available in the United Kingdom. NICE considered the clinical and cost effectiveness of Sativex in the development of its clinical guideline on the management of multiple sclerosis published in 2014. NICE was not able to recommend Sativex as a cost-effective use of NHS resources for the treatment of spasticity in people with multiple sclerosis. Sativex is not therefore routinely funded by the NHS in England for use in the treatment of multiple sclerosis, although clinicians are able to make a request for exceptional funding for individual patients who they think may benefit from treatment.<\/p> NICE has been asked to develop clinical guidelines on cannabis-based products for medicinal use and is expected to look at the clinical and cost effectiveness of treatments, including Sativex, as part of this work. This is expected to be published by October 2019.<\/p>"}
, "answeringMember" : {"_about" : "http://data.parliament.uk/members/4455", "label" : {"_value" : "Biography information for Seema Kennedy"}
}
, "answeringMemberConstituency" : {"_value" : "South Ribble"}
, "answeringMemberPrinted" : {"_value" : "Seema Kennedy"}
, "dateOfAnswer" : {"_value" : "2019-06-27", "_datatype" : "dateTime"}
, "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
, "questionFirstAnswered" : [{"_value" : "2019-06-27T12:43:17.543Z", "_datatype" : "dateTime"}
]}
, "answeringDeptId" : {"_value" : "17"}
, "answeringDeptShortName" : {"_value" : "Health and Social Care"}
, "answeringDeptSortName" : {"_value" : "Health and Social Care"}
, "date" : {"_value" : "2019-06-19", "_datatype" : "dateTime"}
, "hansardHeading" : {"_value" : "Cannabis: Medical Treatments"}
, "houseId" : {"_value" : "1"}
, "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
}
], "questionText" : "To ask the Secretary of State for Health and Social Care, what recent discussions his Department has had with (a) NHS England, (b) drug manufacturers and (c) the National Institute for Health and Care Excellence on funding for licensed cannabis-based products.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
, "tablingMember" : {"_about" : "http://data.parliament.uk/members/4623", "label" : {"_value" : "Biography information for Tonia Antoniazzi"}
}
, "tablingMemberConstituency" : {"_value" : "Gower"}
, "tablingMemberPrinted" : [{"_value" : "Tonia Antoniazzi"}
], "uin" : "266862"}
, {"_about" : "http://data.parliament.uk/resources/1133186", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"}
], "answer" : {"_about" : "http://data.parliament.uk/resources/1133186/answer", "answerText" : {"_value" : " The information is not available in the requested format. The chances of sudden heart attacks in apparently physically fit young people are extremely small. The overwhelming majority of heart attacks happen in elderly people.<\/p> In June 2019 the United Kingdom National Screening Committee (UK NSC) published an evidence summary consultation document in relation to its review of the evidence for screening for the risk of sudden cardiac death in young people (12-39). The review process began in February 2019 and is estimated to be completed by December 2019.<\/p> <\/p> The UK NSC welcomes comments and feedback on the evidence review during the consultation period that lasts from 7 June to 7 September 2019.<\/p> <\/p> The UK NSC is an independent committee that advises Ministers and the National Health Service in all four UK countries on all aspects of screening and supports implementation of screening programmes. Conditions are reviewed against evidence review criteria according to the UK NSC\u2019s evidence review process.<\/p>"}
, "answeringMember" : {"_about" : "http://data.parliament.uk/members/4455", "label" : {"_value" : "Biography information for Seema Kennedy"}
}
, "answeringMemberConstituency" : {"_value" : "South Ribble"}
, "answeringMemberPrinted" : {"_value" : "Seema Kennedy"}
, "dateOfAnswer" : {"_value" : "2019-06-24", "_datatype" : "dateTime"}
, "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
, "questionFirstAnswered" : [{"_value" : "2019-06-24T16:54:04.847Z", "_datatype" : "dateTime"}
]}
, "answeringDeptId" : {"_value" : "17"}
, "answeringDeptShortName" : {"_value" : "Health and Social Care"}
, "answeringDeptSortName" : {"_value" : "Health and Social Care"}
, "date" : {"_value" : "2019-06-19", "_datatype" : "dateTime"}
, "hansardHeading" : {"_value" : "Heart Diseases: Death"}
, "houseId" : {"_value" : "1"}
, "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
}
], "questionText" : "To ask the Secretary of State for Health and Social Care, whether his Department has made an estimate of the number of 14-year-olds today that will die from a sudden cardiac death before they reach their 36th birthday.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
, "tablingMember" : {"_about" : "http://data.parliament.uk/members/1438", "label" : {"_value" : "Biography information for Lord Beamish"}
}
, "tablingMemberConstituency" : {"_value" : "North Durham"}
, "tablingMemberPrinted" : [{"_value" : "Mr Kevan Jones"}
], "uin" : "266733"}
, {"_about" : "http://data.parliament.uk/resources/1133256", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"}
], "answer" : {"_about" : "http://data.parliament.uk/resources/1133256/answer", "answerText" : {"_value" : " This information is not available in the format requested.<\/p> The latest information on suicide registrations for 2017 was published by the Office for National Statistics in September 2018 and can be found at the following link:<\/p>